Turning aging cells into a live vaccine: engineered senescent cancer cells with adjuvant celecoxib for immunotherapy
Curation statements for this article:-
Curated by eLife
eLife Assessment
This important study presents a novel immunotherapy strategy for cancer. The authors develop a whole-tumor cell vaccine comprised of senescent tumor cells and a COX2 inhibitor in a hydrogel matrix. They present convincing evidence of the efficacy of this approach in preclinical models, demonstrating that prostaglandin E2 (PGE2) modulates the senescence-associated secretory phenotype (SASP) toward an immunostimulatory state, although more mechanistic/functional work would strengthen their conclusions. This work is timely and will be of interest to immunologists and others interested in the development of novel cancer therapies.
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (eLife)
Abstract
The immunoactivation effects of senescent tumor cells are a potential avenue for cancer therapy. They can act as antigen reservoirs for cancer vaccination, but how to maintain strong immunogenicity to induce a robust immunity is underexplored. In this study, we developed an engineered live vaccine composed of hydrogel-encapsulated senescent tumor cells and liposomal celecoxib (STCs+CLX-Lipo@Gel). This vaccine prolongs the in vivo persistence of senescent tumor cells and utilizes liposomal celecoxib (COX2 inhibitor) to promote the recruitment and maturation of dendritic cells (DC). Notably, a single dose can significantly delay melanoma growth by eliciting robust immunity. The vaccine extended the survival of mice with melanoma brain metastases. Moreover, this strategy also demonstrated high efficacy against orthotopic pancreatic tumors. This study presents a comprehensive strategy to boost the immunogenicity of whole-tumor-cell vaccines by leveraging senescent tumor cells and COX2 inhibition, with treatment efficacy in various tumor models.
Graphic abstract
Graphic summary.Schematic illustration of the preparation of live-cell vaccines and the tumor-specific immune responses elicited by the vaccine. Created with BioRender.com .
Article activity feed
-
eLife Assessment
This important study presents a novel immunotherapy strategy for cancer. The authors develop a whole-tumor cell vaccine comprised of senescent tumor cells and a COX2 inhibitor in a hydrogel matrix. They present convincing evidence of the efficacy of this approach in preclinical models, demonstrating that prostaglandin E2 (PGE2) modulates the senescence-associated secretory phenotype (SASP) toward an immunostimulatory state, although more mechanistic/functional work would strengthen their conclusions. This work is timely and will be of interest to immunologists and others interested in the development of novel cancer therapies.
-
Reviewer #1 (Public review):
Summary:
The authors aimed to overcome the limitations of whole-tumor-cell vaccines, specifically the weak immunogenicity and rapid clearance often associated with them. They leveraged the unique properties of senescent tumor cells (STCs), which remain metabolically active and secrete chemokines, as a source of antigens. However, to counteract the secretion of the immunosuppressive lipid prostaglandin E2 (PGE2), which is part of the senescence-associated secretory phenotype (SASP), they engineered a hydrogel vaccine formulation (STCs+CLX-Lipo@Gel) containing STCs and liposomal celecoxib (a COX2 inhibitor).
Strengths:
(1) The study is conceptually strong in its approach to leveraging the SASP to improve immunotherapy responses. By selectively inhibiting COX2/PGE2 while preserving the secretion of recruitment …
Reviewer #1 (Public review):
Summary:
The authors aimed to overcome the limitations of whole-tumor-cell vaccines, specifically the weak immunogenicity and rapid clearance often associated with them. They leveraged the unique properties of senescent tumor cells (STCs), which remain metabolically active and secrete chemokines, as a source of antigens. However, to counteract the secretion of the immunosuppressive lipid prostaglandin E2 (PGE2), which is part of the senescence-associated secretory phenotype (SASP), they engineered a hydrogel vaccine formulation (STCs+CLX-Lipo@Gel) containing STCs and liposomal celecoxib (a COX2 inhibitor).
Strengths:
(1) The study is conceptually strong in its approach to leveraging the SASP to improve immunotherapy responses. By selectively inhibiting COX2/PGE2 while preserving the secretion of recruitment chemokines (like CCL2 and CCL5) in the SASP, the authors successfully turn a potentially deleterious cellular state into a therapeutic asset.
(2) Mechanistic Insight: The manuscript provides detailed evidence regarding the mechanism of action. The authors convincingly show that the vaccine restores activity in the NK-DC axis. Specifically, they demonstrate that reducing PGE2 levels enhances NK cell activation (upregulation of NKG2D and NKp46) and promotes the secretion of CCL5 and XCL1 by NK cells, which subsequently recruits cDC1 dendritic cells.
(3) The therapeutic potential is tested across multiple models, including a subcutaneous melanoma model, a difficult-to-treat melanoma brain metastasis model, and an orthotopic pancreatic cancer model. The consistent efficacy across these distinct physiological contexts suggests broad applicability.
Weaknesses:
(1) While the authors successfully inhibit PGE2, the SASP is a complex cocktail of factors. The discussion regarding the long-term presence of these "live" senescent cells is somewhat limited. Although the hydrogel retains cells locally, the potential for other chronic inflammatory factors to eventually promote tumorigenesis or tissue damage in the surrounding niche warrants careful consideration when translating this approach to patients and may require additional preclinical testing.
(2) The study posits that STCs serve as an antigen reservoir. However, the manuscript would benefit from a clearer distinction between whether the immune system is recognizing senescence-specific neoantigens or simply shared tumor antigens that are being presented more effectively due to the adjuvant effect. The authors briefly touch upon neoantigens in the discussion, but the experimental data primarily measure general anti-tumor responses.
Impact:
This work bridges material science and immunology, offering a practical solution to the immunosuppressive barriers of cell-based vaccines. It provides a platform that could potentially be adapted for various solid tumors.
-
Reviewer #2 (Public review):
Summary:
Wang et al. examined an engineered whole-tumor-cell vaccine based on senescent tumor cells co-encapsulated with liposomal celecoxib in a chitosan hydrogel. The authors propose that prolonged persistence of senescent cells, combined with COX2/PGE2 inhibition, restores NK-DC crosstalk, enhances cDC1 recruitment, and ultimately drives robust CD8⁺ T-cell-mediated antitumor immunity. The study is nicely executed and clearly presented, with extensive in vitro and in vivo validation across multiple tumor models, including melanoma brain metastases and orthotopic PDAC. While the overall concept is timely and of potential interest, several mechanistic conclusions are based primarily on correlative evidence and would benefit from additional functional experiments to strengthen causal interpretation and …
Reviewer #2 (Public review):
Summary:
Wang et al. examined an engineered whole-tumor-cell vaccine based on senescent tumor cells co-encapsulated with liposomal celecoxib in a chitosan hydrogel. The authors propose that prolonged persistence of senescent cells, combined with COX2/PGE2 inhibition, restores NK-DC crosstalk, enhances cDC1 recruitment, and ultimately drives robust CD8⁺ T-cell-mediated antitumor immunity. The study is nicely executed and clearly presented, with extensive in vitro and in vivo validation across multiple tumor models, including melanoma brain metastases and orthotopic PDAC. While the overall concept is timely and of potential interest, several mechanistic conclusions are based primarily on correlative evidence and would benefit from additional functional experiments to strengthen causal interpretation and translational relevance.
Strengths:
(1) Strong conceptual framework
(2) Impressive breadth of in vivo models.
(3) Clear immunological readouts.
(4) Innovative combination of senescence biology and biomaterials.
Weaknesses:
(1) Mechanistic conclusions rely heavily on correlation.
(2) Lack of functional immune cell depletion studies.
(3) Limited exploration of long-term safety and antigenic specificity.
Major Critiques:
(1) The authors emphasize the expansion and activation of cDC1 as a key mechanism linking innate and adaptive immunity, yet it does not directly test whether cDC1 is required for the observed CD8⁺ T-cell responses and tumor control.
The authors should perform experiments using Batf3-deficient mice or any other cDC1-depletion strategies to provide important mechanistic validation. If such experiments are not feasible, this limitation should be more clearly acknowledged and discussed.
(2) The authors note that senescence may generate neoantigens distinct from those present in proliferating tumor cells, but the extent to which STC-induced immunity cross-reacts with non-senescent tumor cells is not fully addressed. While it is appreciated that tumor challenge experiments are included, the author should perform a more explicit analysis of antigenic overlap that would strengthen the translational relevance of the approach. For example, they can compare senescence induced by different stimuli or directly assess immune recognition of non-senescent tumor targets, which would help clarify whether the vaccine primarily exploits senescence-specific antigens or broadly shared tumor antigens.
(3) Hydrogel encapsulation clearly extends STC persistence in vivo; however, the study provides limited information on the eventual clearance of these cells and the potential implications of prolonged SASP exposure. Given general concerns regarding chronic inflammation associated with senescent cells, additional discussion of long-term local and systemic responses would be helpful. If extended safety analyses are beyond the scope of the current study, the authors should acknowledge the limitation.
(4) The immunological effects are attributed to COX2/PGE2 inhibition, but it remains unclear whether these effects are specific to celecoxib or could reflect formulation-dependent or off-target mechanisms. The authors may perform additional experiments employing an alternative COX2 inhibitor, genetic COX2 suppression, or PGE2 rescue, which could further support the specificity of the COX2/PGE2-dependent mechanism.
-
